Search results
New lung cancer pill could ‘stop disease in its tracks’
Daily Telegraph· 4 days agoPatients with an incurable form of lung cancer could lead normal lives by taking a daily pill that...
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
Medical Xpress· 6 hours agoA large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 2 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
MAIA Biotechnology reports promising Phase 2 trial results By Investing.com
Investing.com· 6 hours agoThe trial assessed the efficacy of THIO sequenced with the immune checkpoint inhibitor cemiplimab in...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via AOL· 2 hours agoOn Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoThe results showed a 12-month overall survival (“OS”) rate of 69%, a median overall survival (“mOS”) of 17.5 months, and a 30% overall ...
Pfizer's drug for advanced lung cancer shows promising long-term trial results
CNBC· 4 days agoThe company's medicine helped patients live longer without seeing their cancer progress, and most...
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
FierceBiotech· 7 hours agoA new trend has emerged at this year’s American Society of Clinical Oncology conference: the...
...I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Puma Biotechnology (NASDAQ:PBYI)
Benzinga· 1 day agoPuma Biotechnology, Inc. PBYI, a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor ...
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial
MedPage Today· 5 days agoFive-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena)...